HealthQuill Biogen Inc
Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.
Drugs Health Pharma

Biogen’s drug to treat postnatal depression gets UK regulator’s nod

Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.

Read More
Eisai Co., Ltd. and Biogen Inc.’s drug to treat Alzheimer’s disease got marketing authorisation in the European Union, according to a joint statement from the companies.
Drugs Health Pharma

Eisai Co, Biogen Inc.’s Alzheimer’s drug gets EU’s marketing approval

HQ Team April 16, 2025: Eisai Co., Ltd. and Biogen Inc.’s drug to treat Alzheimer’s disease got marketing authorisation in the European Union,.

Read More
Organon has acquired the commercial rights for a biosimilar for intravenous infusion in treating arthritis and Covid-19 from Biogen Inc., for an undisclosed amount.
Drugs Medical Pharma

Organon & Co. buys biosimilar from Biogen for an undisclosed sum

HQ Team April 2, 2025: Organon has acquired the commercial rights for a biosimilar for intravenous infusion in treating arthritis and Covid-19 from.

Read More
Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.
Drugs Health Medical Pharma

Biogen-Eisai’s Alzheimer’s drug gets 4-weekly dosing nod in US

Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.

Read More
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of 30%, according to a Securities and Exchange Commission filing.
Drugs Medical Pharma

Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million

Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.

Read More
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered company has halted its trials.
Drugs Health Pharma

Sage Therapeutics halts trials of experimental drug to treat dementia

Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.

Read More
An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies to halt the trial.
Drugs Health Pharma

Biogen, Sage halt tremor trial after ‘disappointing’ oral drug results

An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies.

Read More
The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.
Drugs Health Pharma

Biogen’s ALS drug gets European Commission’s marketing nod

The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.

Read More
Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug to treat neurodegenerative disease, amyotrophic lateral sclerosis.
Drugs Health Pharma

European regulator backs Biogen’s drug for amyotrophic lateral sclerosis

HQ Team February 24, 2024: Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug.

Read More
Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed to rope in a partner to cut costs of obtaining standard regulatory approval.
Drugs Health Pharma

Biogen abandons Alzheimer’s drug Aduhelm to focus on Leqembi

Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed.

Read More